Key result
Cardio-renal anemia syndrome was independently associated with an increased risk of all-cause death and HF hospitalization in patients with AFMR.
Why the study?
The prognostic impact of cardio-renal anemia syndrome on patients with atrial functional mitral regurgitation was unknown.
Does the presence of cardio-renal anemia syndrome increase the risk of adverse cardiovascular outcomes in patients with atrial functional mitral regurgitation?
Observational (n=986)
Yes
Does the presence of cardio-renal anemia syndrome increase the risk of adverse cardiovascular outcomes in patients with atrial functional mitral regurgitation?
Answers are grounded in this paper and cite their sources.
In patients with moderate-to-severe atrial functional mitral regurgitation, the presence of cardio-renal anemia syndrome is strongly and independently associated with an increased risk of all-cause death and heart failure hospitalization.
Background Atrial functional mitral regurgitation (AFMR) is a common complication in patients with heart failure (HF) and is closely associated with poor cardiovascular (CV) outcomes. Chronic kidney disease (CKD) and anemia are also known to influence the prognosis of HF, and the interaction among them has been termed cardio-renal anemia syndrome (CRAS). Although CRAS has recently been receiving greater attention, its prognostic impact on patients with AFMR has been unknown. Purpose This study aimed to evaluate the association between CRAS and CV outcomes in patients with AFMR. Methods The REVEAL-AFMR is an observational, multicenter, retrospective registry that enrolled patients with moderate-to-severe AFMR in 2019. Patients were stratified into two groups based on the presence or absence of CRAS. CRAS was defined as the case where HF, CKD and anemia were all present. HF was defined as NYHA class Ⅱ, higher, or a history of HF. CKD was defined as estimated glomerular filtration rate <60 mL/min/1.73 m2, and anemia was defined as hemoglobin <13 g/dL in men and <12 g/dL in women. The primary outcome was a composite of all cause death and HF hospitalization. Results A total of 986 patients were included in the analysis, and 258 patients (26.2%) were stratified into the CRAS group. The mean age was 77.7 years and 438 patients (44.4%) were male. Kaplan-Meier analysis revealed significantly higher incidence of composite CV events in the CRAS group compared to the non-CRAS group (Log rank test; p<0.001). This result was consistent across all severities of AFMR. Multivariate Cox proportional hazards regression analysis showed that CRAS was independently associated with CV events (hazard ratio 2.39, 95% confidence interval 1.85-3.09, P<0.001), along with older age, higher NYHA functional class, lower body mass index, and lower systolic blood pressure. Conclusion In patients with AFMR, the presence of CRAS is strongly associated with an increased risk of future CV events. These findings suggest that assessing CRAS may be helpful for risk stratification and management in this population.Cumulative Incidence for CV events
No takes yet. Share an insight, caveat, or question.
Sano et al. (2025) conducted an observational in Atrial functional mitral regurgitation (AFMR) (n=986). Cardio-renal anemia syndrome (CRAS) vs. Absence of CRAS was evaluated on Composite of all cause death and HF hospitalization (HR 2.39, 95% CI 1.85-3.09, p=<0.001). Cardio-renal anemia syndrome was independently associated with an increased risk of all-cause death and HF hospitalization in patients with AFMR.
Synapse has enriched 10 related papers. Consider them for comparative context: